Dosing Principles: How Peptide Protocols Are Actually Built

There is no official dose for most of the peptides in this guide — the numbers in circulation come from animal studies, practitioner surveys and vendor convention. This chapter explains how those numbers are derived, how titration works, and what the reported ranges are for every peptide covered here.

There is no official dose for most of the peptides in this guide — the numbers in circulation come from animal studies, practitioner surveys and vendor convention. This chapter explains how those numbers are derived, how titration works, and what the reported ranges are for every peptide covered here.

Factors That Affect Dosing

Several factors can influence the effectiveness of Argireline, including:

• Skin Type: Oily or dry skin may affect absorption rates.
• Age and Skin Condition: Older skin may require more frequent application for visible results.
• Concurrent Skincare Products: Other active ingredients can interact with Argireline, affecting its efficacy.
• Environmental Factors: Humidity and temperature can impact the absorption and efficacy of topical applications.

Standard Dosing Protocols — worked example: TB-500 (Thymosin Beta-4) Dosing

TB-500 is not FDA-approved for any medical use and is strictly available for research purposes. Consequently, there is no standardized dosing regimen. Research protocols typically involve subcutaneous injections, with dosing often ranging from 2 mg to 5 mg per week, divided into multiple administrations. These figures are derived from preclinical studies and anecdotal reports (PMID 22962027, PMID 23084823).

Titration Protocol: How to Ramp Up Safely

Research protocols implement systematic dose escalation to establish individual tolerance and optimal response thresholds, beginning with 2 ppm concentrations and advancing based on biomarker responses and local tissue tolerance. [1] The standard research titration schedule spans 8 weeks, allowing adequate time for collagen synthesis assessment and adverse reaction monitoring at each dose level.

Research facilities initiate titration with 2 ppm concentrations applied once daily to minimize potential sensitization reactions while establishing baseline response parameters. [2] Tolerance assessment includes visual scoring of erythema (0-4 scale), edema evaluation, and participant-reported symptoms using standardized questionnaires administered at 48-hour intervals. [3]

Dose escalation proceeds only when participants demonstrate stable tolerance (erythema score ≤1, no edema) and show preliminary biomarker responses (≥15% increase in procollagen peptides) at the current dose level. [1] Research protocols mandate 72-hour observation periods between dose increases to capture delayed hypersensitivity reactions and ensure participant safety throughout the escalation process.

Target maintenance dosing typically ranges from 5-10 ppm based on individual response profiles, with research centers maintaining participants at the lowest effective dose that produces measurable collagen synthesis increases (≥25% above baseline). [2] Participants who fail to demonstrate biomarker responses at 10 ppm after 4 weeks are typically classified as non-responders and discontinued from active treatment phases.

Common Dosing Mistakes to Avoid

• Escalating too fast — starting at 200–300 mcg instead of titrating causes water retention and joint aches.
• Inconsistent timing — injecting at random times blunts the GH-pulse benefit; keep to 30-minute windows.
• Poor site rotation — repeated same-site injections cause lipodystrophy and reduce absorption.
• Skipping the empty-stomach rule — eating close to injection (especially carbs/fat) suppresses the GH response.
• Bad storage — freezing reconstituted solution or leaving it at room temperature degrades potency.
• Self-adjusting without labs — chasing symptoms instead of IGF-1 leads to under- or over-dosing.

What Happens If You Miss a Dose

Research protocols typically advise taking a missed dose within 8-12 hours of the scheduled time, given the compound’s estimated 4-6 hour half-life. If more than 12 hours have elapsed, most studies recommend skipping the missed dose and resuming the regular schedule rather than doubling up, which could cause excessive NNMT inhibition.

The timing window reflects the compound’s pharmacokinetic profile and the need to maintain consistent NNMT inhibition without causing dramatic fluctuations in NAD+ levels. Some research protocols allow for dose timing flexibility of ±2 hours from the scheduled administration time to accommodate participant schedules while maintaining study integrity.

Missing multiple consecutive doses (>48 hours) may require restarting the titration schedule in some research protocols, particularly for doses above 150mg daily. This conservative approach accounts for potential tolerance development and ensures participant safety during re-initiation of NNMT inhibition.

Administration Method

Argireline is administered topically. Users should apply the cream or serum to clean, dry skin, focusing on areas prone to wrinkles, such as the forehead and around the eyes. Storage requirements typically involve keeping the product in a cool, dry place to maintain stability. No reconstitution is necessary, as it is provided in ready-to-use formulations.

Reported dose ranges across this guide

Routes of administration mentioned

This article is part of the Peptide Therapy Complete Guide

• Chapter 1. What Is Peptide Therapy? A Plain-English Foundation
• Chapter 2. How Peptides Work: Mechanisms of Action by Class
• Chapter 3. Is Peptide Therapy Safe? Side Effects, Interactions and Long-Term Data
• Chapter 4. The Legal and Regulatory Landscape for Peptides in the United States
• Chapter 5. FDA Compounding Decisions and the 2026 Peptide Rulemaking
• Chapter 6. Dosing Principles: How Peptide Protocols Are Actually Built (you are here)
• Chapter 7. Side Effects Across Peptides: Patterns, Routes and Management
• Chapter 8. What Results to Expect, and When
• Chapter 9. Cost, Insurance and Access: What Peptide Therapy Actually Costs
• Chapter 10. Reconstitution, Administration and Handling
• Chapter 11. How to Choose a Peptide Therapy Clinic
• Chapter 12. Telehealth Peptide Therapy: How Remote Access Works
• Chapter 13. Clinical Protocols and Stacks
• Chapter 14. Weight Loss and Metabolic Peptides: Monographs
• Chapter 15. Growth Hormone and Performance Peptides: Monographs
• Chapter 16. Tissue Repair and Healing Peptides: Monographs
• Chapter 17. Longevity and Anti-Aging Peptides: Monographs
• Chapter 18. Cognitive, Mood and Sleep Peptides: Monographs
• Chapter 19. Skin, Hair and Aesthetic Peptides: Monographs
• Chapter 20. Sexual Health and Hormone Peptides: Monographs
• Chapter 21. Immune and Inflammatory Peptides: Monographs
• Chapter 22. Industry, Market and Research Developments

Previous: Chapter 5. FDA Compounding Decisions and the 2026 Peptide Rulemaking

Next: Chapter 7. Side Effects Across Peptides: Patterns, Routes and Management